SUMMARY In six healthy subjects serum concentrations of 5 amino salicylic acid (SASA) and acetyl 5ASA were measured for up to 24 hours, and urinary excretion over 48 hours. After an intravenous injection of 3.26 mmol 5ASA serum concentrations fell rapidly with a distribution half-life of 17±2 min and an elimination half-life of 42±5 min. After 45 minutes acetyl 5ASA became the dominant compound and after seven hours serum concentrations of both components were almost unrecordable. Orally ingested 5ASA in three preparations to ensure its release in the stomach, small intestine and ileocaecal region respectively gave lower serum concentrations and urinary excretion than those obtained after an intravenous infusion. Bioavailabilities which ranged from 19% for ileocaecal release to 75% for release in the upper gastrointestinal tract, were calculated from areas under the serum concentration curves. Urinary excretion of 5ASA and its acetyl metabolite over 48 hours was 78%, 52%, 55%, and 21% respectively of the dose given intravenously and orally for gastric, small intestinal and ileocaecal release.
Sulphasalazine is an effective treatment for maintenance of clinical remission in ulcerative colitis.' In recent years it has been shown that 5-amino salicylic acid (5ASA) is released from this preparation in the human colon and is the active principle responsible for its effect in colitis.2 Sulphapyridine which is linked by a diazo bond to 5-amino salicylic acid appears to act only as a carrier molecule, but in many patients is responsible for side effects which could be overcome by delivering 5-amino salicylic acid to the colon in some other way. Several preparations have been investigated recently with claims that the drug is released in the human colon to achieve the desired therapeutic effect.3 During its metabolism 5ASA is rapidly converted to the acetyl form and excreted in the urine. 4 Studies of preparations which releasevalue in following the pharmacokinetics of SASA; because of this we have carried out the present study. Normal healthy volunteers took part and were given 5ASA in four different formulations -intravenously and orally in three preparations which ensured release in the stomach, the mid small bowel and the colon. Serum concentrations and urinary excretion were followed for 24 and 48 hours respectively.
Methods

SUBJECTS
Six healthy women between 44 and 58 years of age took part in the study. In 
Results
After intravenous infusion of 0.5 g of SASA high serum concentrations of 5ASA were recorded (mean ±SD, 330±82 ,tmol/l at five minutes) but in the first hour levels fell rapidly ( Figure) , giving a distribution half-life of 17±2 min and an elimination half-life of 42±5 min for the parent compound (Table 1) . At 45 minutes the concentration of acetyl SASA equalled and thereafter exceeded that of 5ASA ( Figure) . Seven hours after the injection, serum concentrations of acetyl SASA and 5ASA were almost unrecordable. Urinary measurements showed that almost all the SASA was excreted within the first four hours, with overall 67% of the total in acetyl form ( Table 2 ). The total amount of 5ASA and acetyl SASA recovered in the urine over 48 hours was 2-6±0-8 mmol which was equivalent to 78±24% of the administered dose.
After ingestion of 5ASA in uncoated gelatin capsules serum concentrations of 234±77, 172±28 smol/l for 5ASA, Ac 5ASA respectively were recorded after two hours, and thereafter fell steadily with only 30-5±17-7 ptmol/l Ac 5ASA present after seven hours (Figure) . Again, almost all of the 5ASA was excreted in the urine within four hours with 59% overall in the acetyl form ( Figure Mean±SDserum concentrations (unolll) of5-aminosalicylicacid (5ASA) and N-acetyl 5ASA in six healthy volunteers after:-(i) a bolus intravenous injection of0.5 g (3.26 mmol) 5ASA; (ii)-(iv) oral ingestion of2.4g (15.7mmol) 5ASA in hard gelatin capsules designed to release their contents in (ii) the stomach, (iii) the midjejunum, (iv) the ileocaecal region.
within 48 hours was 8 2±2 1 mmol which was equivalent to 52±13% of the dose given. The bioavailability calculated from areas under the serum concentration curve was 75%.
Most of the capsules of 5ASA coated with Eudragit-L disintegrated in the small intestine (Table  3) . Radiographs showed only fragments of disrupted capsules when they were in the terminal ileum; most capsules remained intact in the stomach although three were broken at this site. Serum concentrations of 5ASA and acetyl SASA (Figure) were highest at three hours with values of 228±257 and 95±56 ,tmol/l respectively, falling to low values at 12 hours. Most of the drug was excreted in the first 12 hours, particularly in the period four to 12 hours (Table 2) , overall 76% was excreted in the acetyl form. The total urinary excretion over 48 hours was 55 ± 17% of the oral dose. The bio-availability calculated from serum concentration data was 73%.
Most of the S-coated capsules appeared to disintegrate in the terminal ileum or right colon (Table 3) .
No 5ASA or acetyl 5ASA was detected in serum at 3 hours ( Figure) and the highest recorded mean value for acetyl 5ASA was at six hours, 29-7±23-6 gmol/l after which it fell steadily in the next 24 hours. None appeared in the urine in the first four hours and the highest urinary excretion was in the period four to 12 hours (Table 2 ). Total urinary excretion over 48 hours was equivalent to 21±10% of the oral dose given, 86% as acetyl SASA.
Discussion
The intravenous study showed a rapid conversion of 5ASA to the acetyl derivative with an elimination half-life of the parent compound of 42±5 minutes. In the three studies where subjects ingested 15-7 mmol 5ASA to be released in the stomach, midjejunum or ileocaecal region, the pattern and timing of absorption and clearance was related to the site of release. With release in the stomach there was a very high two hour concentration of 5ASA and rapid clearance of The serum and urinary concentrations obtained after ingestion of capsules coated with Eudragit-S were similar to those obtained on previous occasions4 and the overall absorption of the preparation was also similar. 5ASA has not been given intravenously on previous occasions so that the information from this study is new. The release of equivalent doses of 5ASA in the stomach and jejunum showed a marked difference in the concentrations obtained compared with the S-coated preparation which was largely available for absorption in the colon. Because the therapeutic aim in ulcerative colitis is to release 5ASA for a topical effect on inflamed colonic mucosa, it is important that the preparation achieves this. The coating of Eudragit-S ensures release in the ileocaecal region which reduces peak serum concentrations and the overall absorption, but presents a maximum amount of drug for its topical effect on the colonic mucosa. Preparations which are released higher in the gastrointestinal tract are more readily absorbed by the small intestine and will give higher serum concentrations, greater absorption, and a reduction in the SASA available for topical action in the colon.
'Slow release' preparations which begin releasing 5ASA in the upper small intestine may not be ideal because they rely on most of the preparation being released in the colon. In patients with a rapid intestinal transit, slow or delayed release preparations may fail to release the drug, although it was found that Eudragit-S worked satisfactorily in a group of patients who had active symptoms and diarrhoea from their colitis. ' 5-amino salicylic acid appears to be both rapidly absorbed by the small intestine and converted mainly within one hour to the acetyl derivative which is largely excreted within about 12 hours. In contrast, the preparation is only poorly absorbed by the colon and release in the caecal region ensures that serum concentrations are low and overall absorption and urinary excretion are prolonged over 24 hours. 
